S49 Stock Overview A biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Supernus Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Supernus Pharmaceuticals Historical stock prices Current Share Price US$34.20 52 Week High US$35.40 52 Week Low US$23.80 Beta 0.90 1 Month Change 0.59% 3 Month Change 20.42% 1 Year Change 32.56% 3 Year Change 26.67% 5 Year Change 62.86% Change since IPO 730.70%
Recent News & Updates
Independent Director recently sold €295k worth of stock Nov 14
Third quarter 2024 earnings released: EPS: US$0.70 (vs US$0.29 loss in 3Q 2023) Nov 06
Supernus Pharmaceuticals, Inc. Increases Earnings Guidance for the Year 2024 Nov 05
Supernus Pharmaceuticals, Inc. Presents Promising Data from Open-Label Phase 2A Study of SPN-820 Data in Major Depressive Disorder At Psych Congress 2024 Nov 01
Supernus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 22
Supernus Pharmaceuticals, Inc. Announces Data from its Exploratory Open-Label Phase 2a Clinical Study of SPN-820 in Adults with Major Depressive Disorder Oct 18 See more updates
Independent Director recently sold €295k worth of stock Nov 14
Third quarter 2024 earnings released: EPS: US$0.70 (vs US$0.29 loss in 3Q 2023) Nov 06
Supernus Pharmaceuticals, Inc. Increases Earnings Guidance for the Year 2024 Nov 05
Supernus Pharmaceuticals, Inc. Presents Promising Data from Open-Label Phase 2A Study of SPN-820 Data in Major Depressive Disorder At Psych Congress 2024 Nov 01
Supernus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 22
Supernus Pharmaceuticals, Inc. Announces Data from its Exploratory Open-Label Phase 2a Clinical Study of SPN-820 in Adults with Major Depressive Disorder Oct 18
Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA Aug 19
Second quarter 2024 earnings released: EPS: US$0.36 (vs US$0.015 loss in 2Q 2023) Aug 07
Supernus Pharmaceuticals, Inc. Raises Financial Guidance for the Full Year 2024 Aug 07
Supernus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 24
First quarter 2024 earnings released: EPS: US$0.002 (vs US$0.31 in 1Q 2023) May 09
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024 May 09
Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024 May 01
Supernus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 26 Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023
Full year 2023 earnings released: EPS: US$0.024 (vs US$1.13 in FY 2022) Feb 28
Supernus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 14
New minor risk - Insider selling Nov 19
Investor sentiment improves as stock rises 15% Nov 15
Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023 Nov 10
Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.033 profit in 3Q 2022) Nov 09
Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA Nov 04
Supernus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device Oct 11
Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms Sep 12
Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors Aug 22
New minor risk - Shareholder dilution Aug 10
Second quarter 2023 earnings released: US$0.015 loss per share (vs US$0.15 profit in 2Q 2022) Aug 09
Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2023 Aug 09
Supernus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 25
Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 2000 Value-Defensive Index Jun 25
First quarter 2023 earnings released: EPS: US$0.31 (vs US$0.48 in 1Q 2022) May 10
Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023 May 10
Senior Vice President of Quality recently sold €160k worth of stock Mar 17
Full year 2022 earnings released: EPS: US$1.13 (vs US$1.01 in FY 2021) Mar 02
Supernus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 10
Insufficient new directors Nov 16
Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022 Nov 10
Supernus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Supernus Pharmaceuticals, Inc. Provides Regulatory Update on SPN-830 Oct 11
Insufficient new directors Aug 10
Supernus Pharmaceuticals, Inc. Provides Earning Guidance for Full Year 2022 Aug 06
Supernus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 26
Supernus Pharmaceuticals, Inc. announced delayed 10-Q filing May 12 Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022
Supernus Pharmaceuticals, Inc. Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults May 02
Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022 Apr 06 Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year of 2022 Supernus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 28, 2022
Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device Dec 10
Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) completed the acquisition of Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) from Mohr Davidow Ventures and others. Nov 25
Third quarter 2021 earnings released: EPS US$0.41 (vs US$0.76 in 3Q 2020) Nov 05
Investor sentiment improved over the past week Oct 16
Supernus Pharmaceuticals, Inc. Announces Qelbree sNDA for Adult Indication Accepted for Review by FDA Sep 04
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for Full Year 2021 Aug 06
Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.66 in 2Q 2020) Aug 05 Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 3000 Growth Index
Supernus Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Treatment Qelbree for the Treatment of Attention-Deficit Hyperactivity Disorder in Pediatric Patients May 25
Supernus Pharmaceuticals, Inc. Reiterates Full Year 2021 Financial Guidance May 06
Supernus Pharmaceuticals, Inc. announced delayed annual 10-K filing Mar 03
Full year 2020 earnings released: EPS US$2.41 (vs US$2.16 in FY 2019) Feb 28
Revenue misses expectations Feb 28
Supernus Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 24
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA Feb 23
Supernus Pharmaceuticals, Inc. Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients Feb 09
New 90-day high: €24.80 Jan 27
Investor sentiment improved over the past week Jan 13
New 90-day high: €21.80 Jan 12
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD Dec 24
New 90-day high: €21.60 Dec 24
Investor sentiment improved over the past week Dec 24
Supernus Pharmaceuticals, Inc. Announces Executive Changes Nov 20 Supernus Pharmaceuticals, Inc. Provides Regulatory Updates for SPN-812 and SPN-830
Revenue beats expectations Nov 11
Third quarter 2020 earnings released: EPS US$0.76 Nov 11
Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2020 Nov 04
Supernus Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 03, 2020 Oct 29
Supernus Pharmaceuticals, Inc. Announces Executive Changes Oct 06 Supernus Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 18, 2020
Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) acquired USWM Enterprises, LLC from US WorldMeds, LLC. Jul 30 Shareholder Returns S49 DE Pharmaceuticals DE Market 7D -0.6% -2.5% -2.6% 1Y 32.6% -15.6% 6.9%
See full shareholder returns
Return vs Market: S49 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is S49's price volatile compared to industry and market? S49 volatility S49 Average Weekly Movement 4.1% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: S49 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: S49's weekly volatility (4%) has been stable over the past year.
About the Company Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
Show more Supernus Pharmaceuticals, Inc. Fundamentals Summary How do Supernus Pharmaceuticals's earnings and revenue compare to its market cap? S49 fundamental statistics Market cap €1.88b Earnings (TTM ) €57.23m Revenue (TTM ) €624.85m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) S49 income statement (TTM ) Revenue US$651.97m Cost of Revenue US$71.44m Gross Profit US$580.54m Other Expenses US$520.83m Earnings US$59.71m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 20:29 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Emily Bodnar Berenberg David Buck B. Riley Securities, Inc. John Tanner Cantor Fitzgerald & Co.
Show 14 more analysts 
